Research programme: B7H3/PTK7 TOP1i BsADC - Beijing Biocytogen
Alternative Names: B7H3/PTK7 BsADC - Beijing Biocytogen; BCG034Latest Information Update: 28 Aug 2024
At a glance
- Originator Beijing Biocytogen
- Developer Beijing Biocytogen; IDEAYA Biosciences
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours